Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iZafe Group ABFRA:M02 -0.71%48 Cash Ratio is 0.53 as of Mar. 2026, which is 36% above its 10-year median of 0.39. GuruFocus rates FRA:M02 with a GF Score™ of 48/100 and a GF Value™ of €0.04 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 839 Medical Devices & Instruments companies, iZafe Group AB ranks worse than 66.75% on this metric.
iZafe Group AB has a Cash Ratio of 0.53. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for iZafe Group AB's Cash Ratio or its related term are showing as below:
FRA:M02'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.39 Max: 4.93
Current: 0.53
During the past 13 years, iZafe Group AB's highest Cash Ratio was 4.93. The lowest was 0.01. And the median was 0.39.
FRA:M02's Cash Ratio is ranked worse than 66.75% of 839
companies
in the Medical Devices & Instruments industry
Industry Median: 0.98
vs FRA:M02: 0.53
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
iZafe Group AB Cash Ratio Related Terms
iZafe Group AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for iZafe Group AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, iZafe Group AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iZafe Group AB Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where iZafe Group AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iZafe Group AB (FRA:M02) has a Cash Ratio of 0.53 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on iZafe Group AB and its competitors. This is 36% above median its historical median of 0.39. Over the past decade, iZafe Group AB's Cash Ratio has ranged from 0.01 to 4.93. According to the industry distribution chart, iZafe Group AB ranks #560 out of 839 companies in the Medical Devices & Instruments industry, placing it in the top 66.7%.
Is iZafe Group AB's Cash Ratio too high?
iZafe Group AB's current Cash Ratio of 0.53 is 36% above median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 4.93. The Medical Devices & Instruments industry median Cash Ratio is 0.98. iZafe Group AB's value of 0.53 is 45.9% below this industry median. Based on the distribution chart, iZafe Group AB ranks #560 out of 839 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, iZafe Group AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does iZafe Group AB's Cash Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, iZafe Group AB ranks #560 out of 839 companies for Cash Ratio. This places iZafe Group AB in the lower half of its industry. The industry median Cash Ratio is 0.98. iZafe Group AB's value of 0.53 is 45.9% below this benchmark. Historically, iZafe Group AB's own Cash Ratio has ranged from 0.01 to 4.93 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 0.98, iZafe Group AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iZafe Group AB's current Cash Ratio of 0.53 is 45.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on iZafe Group AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iZafe Group AB's current Cash Ratio is 0.53, which is 36% above median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iZafe Group AB stock overvalued right now?
Based on GuruFocus' analysis, iZafe Group AB (FRA:M02) is currently considered Possible Value Trap. The stock's GF Value™ is €0.04, compared to a current price of €0.03 — trading 30% below its estimated fair value. The current Cash Ratio is 0.53, which is 36% above median its 10-year median of 0.39 and 45.9% below the Medical Devices & Instruments industry median of 0.98. iZafe Group AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For iZafe Group AB (FRA:M02), the current Cash Ratio is 0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iZafe Group AB (FRA:M02) Overvalued in 2026?
Based on GuruFocus' analysis, iZafe Group AB stock appears to be undervalued.
The current stock price of €0.03 is trading 30% below its estimated GF Value™ of €0.04.
GuruFocus considers iZafe Group AB to be Possible Value Trap.
Key valuation signals for FRA:M02:
Cash Ratio: 0.53 (36% above median its 10-year median of 0.39)
GF Value™: €0.04 vs. price of €0.03 (30% below fair value)
Industry Position: 45.9% below the Medical Devices & Instruments median (#560 of 839)
No single metric tells the full story. See the FRA:M02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.
48GF Score
Get the complete analysis for FRA:M02
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M02 has been successfully added to your 
